Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

Editor's note: The below transcript has been lightly edited for clarity. Ramiro Ribeiro, MD, PhD: Sure So at Hawaiian Eye, we gave an update on our phase 2 program, the Davio-2 study, that is the ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to ...

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to ...